NewsWatcher

VALEANT Aktie - News & Aktienkurs

15.40 EUR    -1.7%    (Realtime by Tradegate)
Ask: 15.37/ 650 St. - Bid: 15.27/ 655 St.
Tagesumsatz: 20825 St.
Aktienname: Valeant Pharmaceuticals
Land: Kanada
Sektor: Gesundheit
ISIN: CA91911K1021
Wkn: A1C6JH
Index: S&P/TSX 60,S&P/TSX Comp.
Marktkapitalisierung: 5480 Mio. EUR
Umsatz: 10020 Mio. EUR
EBITDA: 4250 Mio. EUR
Gewinn je Aktie: -6.572 EUR
KGV/ KUV/ KCV: - / 0.544 / 1.309
KGV lG/ KGV nG: - / -
Dividendenrendite: -
Letzte Datenerhebung: 23.02.17
 
24.02.17 - 19:45
Sequoia Fund wins dismissal of lawsuit over huge Valeant stake (Reuters EN)
 
NEW YORK, Feb 24 (Reuters) - A New York state judge has dismissed a lawsuit accusing the Sequoia Fund, known for its ties to Warren Buffett, of recklessly making a huge, disastrous investment in Valeant Pharmaceuticals International Inc , causing...
24.02.17 - 17:06
Valeant′s Ugly Earnings History May Repeat Itself (Barrons)
 
Wells Fargo's and his team reiterated an Underperform rating and $10 to $13 valuation range on Valeant Pharmaceuticals (VRX) Friday, writing that the company's 2017 might not be much better than its 2016. Maris lowered his fourth-quarter earnings,...
23.02.17 - 21:27
Exclusive: Clinical-Stage Specialty Pharma EyeGate CEO On Relationship With Valeant (Benzinga)
 
Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) entered into a licensing agreement with Valeant Pharmaceuticals Intl Inc (NYSE: VRX) Tuesday regarding its EyeGate II Delivery System and EGP-437 corticosteroid combination for post-operative ocular patients...
23.02.17 - 17:48
Former Valeant and Philidor execs plead not guilty in fraud scheme (Reuters EN)
 
NEW YORK (Reuters) - A former Valeant Pharmaceuticals International Inc executive and the former chief executive of mail order pharmacy Philidor Rx Services pleaded not guilty on Thursday to charges they orchestrated a multi-million dollar fraud and ...
23.02.17 - 17:21
Did 50 Salespeople Leave Valeant? Wells Fargo Investigates (Barrons)
 
Wells Fargo's and his team reiterated an Underperform rating and $10 to $13 valuation range on Valeant Pharmaceuticals (VRX) Thursday, following talks with the firm about recents staffing moves. First they asked Valeant to address rumors in the ind...
23.02.17 - 13:54
Research Reports Coverage on Healthcare Stocks -- Valeant Pharma, CVS Health, Express Scripts, and UnitedHealth (PR Newswire)
 
NEW YORK, February 23, 2017 /PRNewswire/ -- This morning, Stock-Callers.com dedicates its attention to these Healthcare stocks: Valeant Pharmaceuticals International Inc. (NYSE: VRX), CVS Health Corp. (NYSE: CVS), Express Scripts Holding Co. (NAS...
23.02.17 - 13:42
BRIEF-Valeant unit Obagi Medical Products collaborates with Nextcell Medical (Reuters EN)
 
* Obagi Medical Products-collaboration with Nextcell Medical Co to claim exclusive distribution of Suzan Obagi's line of skin care products throughout U.S. Source text for Eikon: Further company coverage:...
22.02.17 - 10:54
Valeant: Price Target Over $30 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.02.17 - 22:09
Valeant Acquires Eyegate Licensing Rights (The Street)
 
Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...
21.02.17 - 18:48
18 Biggest Mid-Day Gainers For Tuesday (Benzinga)
 
Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) shares surged 63.4 percent to $2.68 as the company reported a licensing agreement with Valeant. Latest Ratings for EYEG DateFirmActionFromTo Apr 2016Noble FinancialInitiates Coverage onBuy Nov 2015Maxi...
21.02.17 - 17:06
Global Cosmetic Surgery Market - Forecasts from 2016 to 2021 - Key Players are Sanofi S.A, Valeant Pharmaceuticals … (Business Wire EN)
 
Research and Markets has announced the addition of the "Global Cosmetic Surgery Market - Forecasts from 2016 to 2021" report to their offering....
21.02.17 - 16:07
Valeant Shares Are Worth At Least $57 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.02.17 - 16:01
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson (Zacks)
 
The Zacks Analyst Blog Highlights: Merck, Valeant Pharmaceuticals International, Allergan, AstraZeneca and Johnson & Johnson...
21.02.17 - 15:31
BRIEF-Eyegate Pharmaceuticals says under license agreement, Valeant to make upfront payment of $4.0 mln - SEC filing (Reuters EN)
 
* Eyegate Pharmaceuticals Inc - under license agreement, Valeant will pay company an upfront payment of $4.0 million - SEC filing...
21.02.17 - 15:12
BRIEF-Valeant Pharmaceuticals and EyeGate enter into licensing agreement for EGP-437 combination product (Reuters EN)
 
* Valeant Pharmaceuticals and EyeGate enter into licensing agreement for EGP-437 combination product in post-operative pain and inflammation in ocular surgery patients...
21.02.17 - 15:01
20 Stocks Moving In Tuesday′s Pre-Market Session (Benzinga)
 
Gainers Eyegate Pharmaceuticals Inc (NASDAQ: EYEG) rose 44.2 percent to $2.35 in pre-market trading as the company reported a licensing agreement with Valeant. read more...
21.02.17 - 13:45
EyeGate Pharma surges 15% on news of Valeant licensing agreement (MarketWatch)
 
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...
21.02.17 - 09:32
Sobi Enters Into new Distribution Agreement With Valeant for Ammonul® (PR Newswire)
 
STOCKHOLM, Feb 21, 2017 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) today announces that the company has entered into a 3-year agreement with Valeant Pharmaceuticals Ireland for the distribution of Ammonul® (sodium phenyl acetate an...
20.02.17 - 16:43
Is Valeant Pharmaceuticals Intl Inc. “Investable?” (Fool)
 
Debt and scandal aside, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) might very well be a very good contrarian investment thanks to these three factors....
19.02.17 - 10:45
Is Siliq A New Beginning For Valeant? (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
17.02.17 - 15:54
Valeant Pharmaceuticals-Aktie: gute Nachrichten! - Aktienanalyse (Aktiencheck)
 
London (www.aktiencheck.de) - Valeant Pharmaceuticals-Aktienanalyse des Analysten Douglas Tsao von Barclays: Douglas Tsao, Aktienanalyst beim Investmenthaus Barclays, rät Investoren laut einer Aktienanalyse weiterhin zu einer Gleichgewichtung der Ak...
17.02.17 - 12:13
Valeant gets FDA approval for SILIQ to treat moderate-to-severe plaque psoriasis (PBR)
 
The US Food and Drug Administration (FDA) has approved Valeant Pharmaceuticals International's Biologics License Application (BLA) for SILIQ (brodalumab) injection, for subcutaneous use, a monoclonal antibody that targets the IL-17 receptor for pat...
17.02.17 - 07:30
Millionendepot: Valeant - Kursziel 27 Euro (IRW Press)
 
Millionendepot:  Valeant - Kursziel 27 Euro Freitag, 17. Februar 2017 Sehr geehrte Investoren, Valeant Pharmaceuticals ist ein kanadisches Unternehmen das durch das Aufkaufen von Medikamenten sowie......
16.02.17 - 22:43
Don′t Count on Valeant′s New Drug to Save the Day (Fool)
 
The approval of Valeant's new psoriasis drug Siliq is good news, but investors will want to temper their expectations for the drug....
16.02.17 - 19:24
Valeant Surrenders Early Gains After SILIQ′s FDA Approval (Benzinga)
 
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are trading lower by $0.42 (2.6 percent) at $16.44 in Thursday's session. Before the open, the company announced it received FDA approval for SILIQ (a treatment for Psoriasis). read more...
16.02.17 - 18:12
Valeant: Brodalumad Approval Won′t End Woes (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
16.02.17 - 18:07
Why This FDA Approval for Valeant Is Not as Good as First Thought (24/7 Wall St.)
 
Um den gesamten Artikel unter feedproxy.google.com zu lesen, klicken Sie bitte auf die Überschrift...
16.02.17 - 17:07
FDA approves Valeant′s psoriasis treatment (Proactive Investors)
 
The US Food and Drug Administration (FDA) has approved Valeant Pharmaceuticals Inc's (NYSE:VRX) Siliq to treat adults with moderate-to-severe plaque psoriasis. Plaque psoriasis - the most common form of the autoimmune disorder psoriasis - causes su...
16.02.17 - 16:51
Valeant Pharmaceuticals: Dead in the Water? (Barrons)
 
Barclays analyst Douglas Tsao and team call the approval "good news." They explain why: VRX received a measure of good news with the FDA's approval of brodalumab, given the brand name Siliq, which was accompanied with a black box warning and REMS pr...
16.02.17 - 15:21
Morning Movers: Valeant Jumps, Kate Spade Soars, MGM Drops (Barrons)
 
Stocks look set for a lower open this morning following yesterday's new highs in the major indexes. S&P 500 futures have dropped 0.2%, while Dow Jones Industrial Average futures have fallen 0.2%. Nasdaq ......
16.02.17 - 13:27
AstraZeneca′s Partner Receives US Approval For Siliq Injection (Alliance)
 
LONDON (Alliance News) - Pharmaceutical giant AstraZeneca PLC on Thursday said its partner Valeant Pharmaceuticals has received approval from the US Food & Drug Administration for the Siliq injection.Under......
16.02.17 - 13:26
Valeant stock surges 3% after psoriasis drug gets FDA approval (MarketWatch)
 
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...
16.02.17 - 13:24
BRIEF-Astrazeneca says will get $130 mln as milestone payment after Brodalumab approval (Reuters EN)
 
* Partner Valeant Pharmaceuticals announced that US FDA has approved Siliq (Brodalumab) injection for treatment of adult patients with moderate-to-severe plaque psoriasis...
16.02.17 - 00:42
FDA approves Valeant′s drug to treat plaque psoriasis (Reuters EN)
 
Feb 15 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Valeant Pharmaceuticals International Inc's Siliq to treat adults with moderate-to-severe plaque psoriasis....
15.02.17 - 18:36
Wall Street Buys Valeant After Ackman Cuts Stake (Benzinga)
 
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are trading higher by $0.80 (4.8 percent) at $16.78 in Wednesday's session. read more...
15.02.17 - 16:54
These 3 Hedge Funds Are Playing With Fire (Fool)
 
These money managers own a combined 15.1% of embattled drugmaker Valeant Pharmaceuticals, which may not be a smart move....
15.02.17 - 00:09
Valeant: Time To Go Long (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
14.02.17 - 23:26
Ackman boosted Chipotle holdings, pared Valeant in 4th quarter (MarketWatch)
 
Um den gesamten Artikel unter marketwatch.com zu lesen, klicken Sie bitte auf die Überschrift...
14.02.17 - 20:01
Valeant′s Stock Having One Of Its Best Days Of 2017 (Benzinga)
 
Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares are trading higher by $0.90 (6 percent) at $15.86 in Tuesday's session. read more...
14.02.17 - 16:54
Valeant: Why $3.75 Billion is the Most Important Number (Barrons)
 
Valeant Pharmaceuticals International (VRX) is scheduled to report earnings on Feb. 28, and analysts haven't been shy about making their opinions on the stock known before judgment day. Barclays pointed ......
14.02.17 - 16:21
Update On Valeant′s Debt Pathway After Asset Sales (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
14.02.17 - 15:33
Valeant, Pershing Square Will Split Legal Costs on Allergan Lawsuit (The Street)
 
Um den gesamten Artikel unter thestreet.com zu lesen, klicken Sie bitte auf die Überschrift...
13.02.17 - 23:42
BRIEF-Valeant says Co, J. Michael Pearson, Pershing Square and William Ackman entered litigation management agreement (Reuters EN)
 
* Says co, j. Michael pearson and pershing square capital management and william ackman entered into a litigation management agreement...
13.02.17 - 23:18
Valeant Pharmaceuticals To Participate At Healthcare Conferences (PR Newswire)
 
LAVAL, Quebec, Feb. 13, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that Joseph C. Papa, Chairman and CEO, will participate in the following healthcare conferences: 2017 RBC Capita...
13.02.17 - 20:31
Valeant: A Major Run Is Underway (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
13.02.17 - 16:30
Valeant Pharmaceuticals-Aktie: ist eine aggressivere Rekapitalisierung notwendig? - Aktienanalyse (Aktiencheck)
 
London (www.aktiencheck.de) - Valeant Pharmaceuticals-Aktienanalyse des Analysten Douglas Tsao von Barclays: Douglas Tsao, Aktienanalyst beim Investmenthaus Barclays, rät Investoren laut einer Aktienanalyse weiterhin zu einer Gleichgewichtung der Ak...
13.02.17 - 15:54
Stock Options Trades: Covered-Call Alerts for Apple, Microchip Technology, Skechers, Valeant Pharmaceuticals and Yelp (PR Newswire)
 
CHICAGO, Feb. 13, 2017 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, MCHP, SKX, VRX, and YELP. To see the high-return covered-call trades uncovered by InvestorsObserver's analysts, read the InvestorsObserver's Pr...
10.02.17 - 21:12
Cory Booker Dissents On Importing Cheaper Drugs; A Victory For Valeant? (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
10.02.17 - 20:36
Corey Booker Dissents On Importing Cheaper Drugs; A Victory For Valeant? (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
10.02.17 - 20:15
Valeant Pharmaceutcials: I Guess That′s Why They Call It ′Equal Weight′ (Barrons)
 
It seems almost impossible to have a middle of the road opinion on Valeant Pharmaceuticals International (VRX). Then there's Barclays analyst Douglas Tsao and team, who refuse to stake out a position, even as they cut their price target to $20 from...





































 

>Aktiensuche

>Wertpapiersuche

>Finanznachrichten posten

Boersentreff Media:            >Impressum            >Über uns            >Werbung            >Newstechnologie

>Zitat des Tages: Was man nicht braucht ist mit einem Heller noch zu teuer bezahlt. - Seneca

Partner:    >Tradegate Börse | >DB Xmarkets | >TraderFox Handelssignale | >Heibel-Ticker Börsenbrief | >Finanzlinks

Börsentreff auf Facebook | Börsentreff auf Twitter

Copyright @ Boersentreff.de - Die Märkte im Blick!